CURRENT APPROACHES TO CONTROL OF ISONIAZID-RESISTANT TUBERCULOSIS

Authors

  • Vladimir Milanov Department of Pulmonary Diseases, Medical University – Sofia, Hospital of respiratory diseases “St. Sofia”, Sofia, Bulgaria
  • Nikolay Yanev Department of Pulmonary Diseases, Medical University – Sofia, Hospital of respiratory diseases “St. Sofia”, Sofia, Bulgaria
  • Natalia Gabrovska Specialized hospital for active treatment of children diseases “Prof. Ivan Mitev”, Sofia, Bulgaria
  • Denitsa Dimitrova Department of Pulmonary Diseases, Medical University – Sofia, Hospital of respiratory diseases “St. Sofia”, Sofia, Bulgaria
  • Elizabeta Bachiyska National Reference Laboratory of Tuberculosis, National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria
  • Vania Youroukova Department of Pulmonary Diseases, Medical University – Sofia, Hospital of respiratory diseases “St. Sofia”, Sofia, Bulgaria

DOI:

https://doi.org/10.58395/pipd.v50i1.83

Keywords:

Tuberculosis, Isoniazid, Drug resistance, Diagnosis, Treatment

Abstract

Isoniazid (H; INH) is an important first-line drug for the treatment of active tuberculosis (TB) and latent TB infection because of its potent early bactericidal activity against Мycobacterium tuberculosis. Currently, TB resistant to INH, alone or in combination with other drugs, is the most common type of drug-resistant TB.

Epidemiology of INH-resistant TB, the molecular mechanisms of drug resistance, current methods for diagnosis and therapeutic regimens of this TB form are presented.

Studies in the last years have shown that resistance to INH reduces the probability of treatment success and increases the risk of acquiring resistance to other impor­tant first-line drugs.

Based on the most recent meta-analyses, the last WHO recommendations for treatment of INH-resistant TB are to include rifampicin (RIF), ethambutol, pyrazinamide and levofloxacin for 6 months, and not to add streptomycin or other injectable agents to the drug regimen. The guideline emphasizes the importance of excluding resistance to RIF before starting the regimen for INH-resistant TB because of the risk for development of multidrug-resistant TB during the treatment course.

The WHO recommendations are based on observational studies, not randomized controlled trials, and are thus conditional and based on low certainty in the estimates of effect. There­fore, further work is needed to optimize the treatment and control of INH-resistant TB.

References

Global tuberculosis report 2021. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Xi Y, Zhang W, Qiao R-J, Tang J (2022) Risk factors for multidrug-resistant tuberculosis: A worldwide systematic review and meta-analysis. PLoS ONE 17(6): e0270003. https://doi.org/10.1371/journal.pone.0270003.

Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. JAMA 1993;270:65-8.

Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998;2:10-5.

Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med 1995;332:336-7.

Global tuberculosis report 2020. Geneva: World Health Organization; 2020. License: CC BY-NC-SA 3.0 IGO.

Hoopes AJ, Kammerer JS, Harrington TA, Ijaz K, Armstrong LR. Isoniazid-monoresistant tuberculosis in the United States, 1993 to 2003. Arch Intern Med 2008;168:1984-92.

Jenkins HE, Zignol M, Cohen T. Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. PLoS One 2011;6:e22927.

Dean AS, Zignol M, Cabibbe AM, Falzon D, Glaziou P, Cirillo DM, et al. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data. PLoS Med. 2020; 17(1): e1003008. https://doi.org/10.1371/journal.pmed.1003008.

European Centre for Disease Prevention and Control, WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2022 – 2020 data. Copenhagen: WHO Regional Office for Europe and Stockholm: European Centre for Disease Prevention and Control; 2022. Licence: CC BY 3.0 IGO.

European Centre for Disease Prevention and Control. Report of the joint ECDC and WHO review of the national tuberculosis programme in Bulgaria. Stockholm: ECDC; 2014. ISBN 978-92-9193-598-7. doi 10.2900/37158.

Goering R., R.I.M., Mims C. Medical Microbiology, Chapter 5. Diagnosis and control; Resistance to Antibacterial Agents. 4th ed 2007: Mosby.

Pfyffer, G.E. Drug-resistant tuberculosis: resistance mechanisms and rapid susceptibility testing. Schweizerische medizinische Wochenschrift, 2000. 130(49):1909-13.

Miotto P, Tessema B, Tagliani E, et al. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis. Eur Respir J 2017; 50: 1701354 [https://doi.org/10.1183/13993003.01354-2017].

Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992;358:591-3.

Piatek AS, Telenti A, Murray MR, El-Hajj H, Jacobs WR Jr, Kramer FR, et al. Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob Agents Chemother 2000;44:103-10.

Ramaswamy SV, Reich R, Dou SJ, Jasperse L, Pan X, Wanger A, et al. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003;47:1241-50.

Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998;79:3-29.

Dalla Costa ER, Ribeiro MO, Silva MS, Arnold LS, Rostirolla DC, Cafrune PI, et al. Correlations of mutations in katG, oxyR-ahpC and inhA genes and in vitro susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype families from tuberculosis prevalent countries in South America. BMC Microbiol 2009;9:39.

Palomino JC, Martin A. Drug Resistance Mechanisms in Mycobacterium tuberculosis. Antibiotics. 2014; 3(3):317-340.

Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994;263:227-30.

Jhun BW, Koh WJ. Treatment of isoniazid-resistant pulmonary tuberculosis. Tuberc Respir Dis (Seoul). 2020;83:20–30. doi:10.4046/trd.2019.0065.

Ministry of Health of the Republic of Bulgaria. Methodological guideline on microbiological diagnosis of tuberculoosis, 2016. Approved by Order No. RD-01-72 / 10.03.2016. Available on: http://www.mh.government.bg/. In Bulgarian.

Martin A, Panaiotov S, Portaels F, Hoffner S, Palomino JC, Angeby K. The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother. 2008 Jul;62(1):56-64. doi: 10.1093/jac/dkn139. Epub 2008 Apr 10. PMID: 18407918.

Ministry of Health of the Republic of Bulgaria. Methodological guideline on organization of the performance of fast methods for diagnosis of tuberculosis on the territory of the Republic of Bulgaria, 2015. Approved by Order No. RD -01-237/16.10.2015. Available on: http://www.mh.government.bg/. In Bulgarian.

MacPherson, P. (2018). Emerging Issues in tuberculosis. K4D Reading Pack. Brighton, UK: Institute of Development Studies; p. 56.

Tagliani E, Anthony R, Kohl TA, et al. Use of a whole genome sequencing-based approach for Mycobacterium tuberculosis surveillance in Europe in 2017–2019: an ECDC pilot study. Eur Respir J 2021; 57: 2002272 [https://doi.org/10.1183/13993003.02272-2020].

Yordanova, S., Baykova, A., Atanasova, Y., Todorova, Y., Bachiyska, E. Isoniazid-monoresistant tuberculosis in Bulgaria. Probl. Inf. Paras. Dis., Vol. 48, 2020, 1, 21-24.

Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 2009;6:e1000146.

Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009;6:e1000150.

WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.

WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO.

Downloads

Published

2022-10-14

How to Cite

Milanov, V., Yanev, N., Gabrovska, N., Dimitrova, D., Bachiyska, E., & Youroukova, V. (2022). CURRENT APPROACHES TO CONTROL OF ISONIAZID-RESISTANT TUBERCULOSIS. PROBLEMS of Infectious and Parasitic Diseases, 50(1), 25–31. https://doi.org/10.58395/pipd.v50i1.83

Issue

Section

Articles

Most read articles by the same author(s)